病理淋巴结阳性前列腺癌放疗联合ADT后的复发模式:多机构研究
多机构回顾性纳入270例病理淋巴结阳性前列腺癌患者,接受放疗±雄激素剥夺治疗(ADT),中位随访48个月。4年生化无进展生存(bPFS)总体为72%,放疗前PSA<0.1 ng/mL者为83%,PSA>2 ng/mL者为35%(P<.0001)。多变量分析显示放疗前PSA>0.5、长程ADT、Grade group 4及切缘阳性与bPFS显著相关。
要点
- 270例pN1前列腺癌患者接受放疗±ADT,中位随访48个月,4年bPFS总体72%。
- 放疗前PSA<0.1 ng/mL者4年bPFS 83%,PSA>2 ng/mL者仅35%(P<.0001)。
- 多变量分析中长程ADT对比无ADT(HR 0.43)及对比短程ADT(HR 0.34)与bPFS显著相关。
核心结论
- 前列腺切除术后放疗时PSA<0.5 ng/mL与pN1前列腺癌患者较好的bPFS相关。
研究设计与样本
- 多机构回顾性队列研究,纳入4家学术机构的270例病理淋巴结阳性(pN1)前列腺癌患者,接受放疗联合短程(≤6个月)或长程(>6个月)ADT,中位随访48个月。
主要发现
- 256例(95%)有包膜外侵犯,70%有精囊侵犯,59%切缘阳性,49%为Grade group 5,64%术后PSA可检测(>0.1 ng/mL)。
- ADT为短程者占20%,长程者占68%(中位24个月),26例(10%)未接受ADT。
- 生化失败(bF)见于29%,其中5%为盆腔淋巴结失败,11%为远处转移。
- 4年bPFS总体为72%,放疗前PSA<0.1 ng/mL者为83%,PSA 0.1至<0.5 ng/mL者为76%,PSA 0.5至2 ng/mL者为60%,PSA>2 ng/mL者为35%(P<.0001)。
- 多变量分析中,放疗前PSA 0.5-2.0 vs <0.1的HR为2.97,>2.0 vs <0.1的HR为7.63;长程ADT vs 无ADT的HR为0.43,长程ADT vs 短程ADT的HR为0.34;Grade group 4 vs 2的HR为4.11;切缘阳性的HR为1.773,均与bPFS显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluate prognostic factors and patterns of recurrence in patients who received RT ± androgen deprivation therapy (ADT) for pathologic node-positive (pN1) prostate cancer (PCa) in a multi-institutional cohort. METHODS AND MATERIALS: Data from patients with pN1 PCa and received RT with short-term (ST, ≤6 mo) or long-term (LT, >6 mo) ADT were obtained from 4 academic institutions. Biochemical progression-free survival (bPFS) and distant metastasis-free survival (DMFS) were evaluated. RESULTS: Two hundred seventy patients were included, with a median follow-up of 48 months. Two hundred fifty-six (95%) patients had extracapsular extension, 70% had seminal vesicle invasion, 59% had positive surgical margins, 49% had grade group 5, and 64% had a detectable (>0.1 ng/mL) postoperative prostate-specific antigen (PSA). ADT was ST (20%) or LT (68%, median 24 months), whereas 26 (10%) received no ADT. Biochemical failure (bF) was observed in 29%, with 5% having pelvic nodal failure and 11% having distant metastases. The 4-year bPFS was 72% overall, and was 83% for a pre-RT PSA of <0.1 ng/mL, 76% for PSA 0.1 to <0.5 ng/mL, 60% for PSA 0.5 to 2 ng/mL, and 35% for PSA > 2 ng/mL (P < .0001). On multivariable analysis, pre-RT PSA > 0.5 (0.5-2.0 vs <0.1 hazard ratio (HR), 2.97; >2.0 vs <0.1 HR, 7.63), use of LT ADT versus no ADT (HR, 0.43) and use of LT ADT compared to ST ADT (HR, 0.34), Grade group 4 versus 2 (HR, 4.11), and positive surgical margins (HR, 1.773) were significantly associated with bPFS. CONCLUSIONS: Postprostatectomy RT at PSA < 0.5 ng/mL is associated with favorable bPFS in pN1 PCa.
引用
- Ballas LK, Reddy CA, Han HR, et al. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2024. PMID: 39733964. doi:10.1016/j.prro.2024.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。